Around 2 million people are diagnosed with lung cancer annually, causing 20,000 deaths.
Non-small cell carcinomas account for 80− 85% of lung cancer cases. Over the last few …

Background: Drug development is often inefficient, costly and lengthy, yet it is essential for
evaluating the safety and efficacy of new interventions. Compared with other disease areas …

Anaplastic lymphoma kinase (ALK) fusion gene‐positive lung cancer often shows brain
metastasis at initial diagnosis or during the course of treatment. However, molecular …

To evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+
non-small cell lung cancer patients and crizotinib efficacy in different lines. This national …

Loss-of-function mutations in KEAP1 frequently occur in lung cancer and are associated with
poor prognosis and resistance to standard of care treatment, highlighting the need for the …

Abstract Background About 3%–5% of non‐small cell lung cancer (NSCLC) presents
positive anaplastic lymphoma kinase (ALK). Recently, several target agents have been …

ABSTRACT INTRODUCTION Anaplastic Lymphoma Kinase (ALK)-rearranged advanced
non-small cell lung cancer (aNSCLC) represents 4% of all NSCLC, and multiple ALK …

Among the many reports published on strategies applicable to synthesizing pyrazolines and
its analogs, The 1, 3-dipolar cycloaddition offers a remarkably wide range of utility. Many 1, 3 …

Lung cancer is among the leading causes of death related to cancer globally, with NSCLC
(non-small cell lung cancer) accounting for about 85% of all cases. NSCLC is characterized …

The number of targeted therapies licenced for non-small cell lung cancer (NSCLC) has
increased substantially in recent years, resulting in a major increase in demand for genomic …